Testosterone Replacement Therapy in Advanced Chronic Kidney Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00645658
Recruitment Status : Completed
First Posted : March 28, 2008
Last Update Posted : May 7, 2012
Information provided by (Responsible Party):
Kevin Leigh McIntire, Stanford University

Brief Summary:
Muscle wasting is common in advanced chronic kidney disease (CKD) and adversely affects morbidity and mortality. In 2/3 of males with advanced CKD serum testosterone (TT) levels are reduced, and likely contributes to the wasting. As TT in relatively safe physiologic replacement doses, increases muscle mass in otherwise normal TT deficient subjects, we hypothesize that physiologic TT replacement will be effective in preventing and treating the loss of muscle mass and function in CKD patients, will improve quality of life and may reduce some cardiovascular disease (CVD) risk factors.

Condition or disease Intervention/treatment Phase
Kidney Failure Kidney Diseases Drug: Testim (1% testosterone gel) Not Applicable

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 17 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Testosterone Replacement Therapy in Advanced Chronic Kidney Disease
Study Start Date : August 2007
Actual Primary Completion Date : August 2010
Actual Study Completion Date : August 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Kidney Diseases

Intervention Details:
  • Drug: Testim (1% testosterone gel)
    Subjects apply contents of gel packet to skin daily.

Primary Outcome Measures :
  1. Lean body mass [ Time Frame: pre and post treatment ]
  2. Fat mass [ Time Frame: pre and post treatment ]
  3. Thigh cross sectional area [ Time Frame: pre and post treatment ]

Secondary Outcome Measures :
  1. Quadriceps strength [ Time Frame: pre and post treatment ]
  2. Physical Function [ Time Frame: pre and post treatment ]
  3. Quality of Life [ Time Frame: pre and post treatment ]
  4. Inflammatory markers [ Time Frame: pre treatment and monthly until end of treatment ]
  5. Muscle atrophy signaling pathways [ Time Frame: pre and post treatment ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   45 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:Inclusion criteria: CKD subjects; males with calculated GFR (MRDR equation) between 15 and 40 ml/min/1.73m2 and stable or slowly progressive renal failure (decline in function of <1ml/min/month) including those patients requiring hemodialysis and serum testosterone levels of <300 ng/ml and capable of safely performing required exercise testing and serum testosterone levels of <300ng/ml and capable of safely performing required exercise testing.

Control subjects; good health, normal serum creatinine levels, normal TT levels and able to perform required exercise testing safely. The racial and ethnic composition of the subjects will reflect the composition present in the ESRD population in the counties in Northern California from which our patients are referred. Subjects to be of age 45-80 years.

Exclusion Criteria:Exclusion criteria: applicable to both CKD and control subjects. Any unstable chronic medical condition, previous kidney transplant. Uncontrolled diabetes mellitus, active vasculitis, active autoimmune disease, malignancy(<5 yrs), obesity (BMI > 35), alcoholism or other recreational drug use, active heart disease, angina, uncontrolled arrhythmias or myocardial infarct within past 3 months, peripheral vascular disease with claudication, active lung, liver or GI disease, sleep apnea, medically unstable subjects and subjects who received anabolic, catabolic or cytotoxic medications during the prior 3 months. History of prostate CA, PSA >4g/ml, or advanced BPH (AUA symptom score > 21) and abnormal prostate on digital rectal examination. Bone or joint abnormalities that would preclude exercise testing.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00645658

United States, California
VA Palo Alto Health Care System
Palo Alto, California, United States, 94304
Santa Clara Valley Medical Center
San Jose, California, United States, 95128
Sponsors and Collaborators
Stanford University
Principal Investigator: Ralph Rabkin Stanford University

Responsible Party: Kevin Leigh McIntire, Postdoctoral Scholar, Stanford University Identifier: NCT00645658     History of Changes
Other Study ID Numbers: SU-12112007-932
IRB# 10132
First Posted: March 28, 2008    Key Record Dates
Last Update Posted: May 7, 2012
Last Verified: May 2012

Additional relevant MeSH terms:
Kidney Diseases
Renal Insufficiency, Chronic
Renal Insufficiency
Urologic Diseases
Testosterone enanthate
Testosterone undecanoate
Testosterone 17 beta-cypionate
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Anabolic Agents